Anixa Biosciences Inc (ANIX) - Total Liabilities
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has total liabilities worth $1.64 Million USD as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anixa Biosciences Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Anixa Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Anixa Biosciences Inc to evaluate short-term liquidity relative to the company's equity base.
Anixa Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Anixa Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MaxCyte Inc
NASDAQ:MXCT
|
USA | $33.20 Million |
|
Fortune Information Systems Corp
TW:2468
|
Taiwan | NT$1.12 Billion |
|
LIG-ES SPAC
KQ:220260
|
Korea | ₩54.42 Billion |
|
Aspire Mining Ltd
AU:AKM
|
Australia | AU$679.08K |
|
Cayman Engley Industrial Co
TW:2239
|
Taiwan | NT$18.39 Billion |
|
Seker Gayrimenkul Yatirim Ortakligi A.S.
IS:SEGYO
|
Turkey | TL1.08 Billion |
|
ShareHope Medicine Co Ltd
TWO:8403
|
Taiwan | NT$2.78 Billion |
|
Sucro Limited
V:SUGR
|
Canada | CA$515.60 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down Anixa Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Anixa Biosciences Inc (ANIX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anixa Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anixa Biosciences Inc (1985–2025)
The table below shows the annual total liabilities of Anixa Biosciences Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $2.13 Million | -21.20% |
| 2024-10-31 | $2.70 Million | +25.66% |
| 2023-10-31 | $2.15 Million | -2.76% |
| 2022-10-31 | $2.21 Million | +48.40% |
| 2021-10-31 | $1.49 Million | +25.41% |
| 2020-10-31 | $1.19 Million | -19.76% |
| 2019-10-31 | $1.48 Million | +17.09% |
| 2018-10-31 | $1.27 Million | +42.23% |
| 2017-10-31 | $889.49K | -80.83% |
| 2016-10-31 | $4.64 Million | +8.38% |
| 2015-10-31 | $4.28 Million | -15.14% |
| 2014-10-31 | $5.05 Million | -42.40% |
| 2013-10-31 | $8.76 Million | +27.80% |
| 2012-10-31 | $6.85 Million | -9.66% |
| 2011-10-31 | $7.59 Million | +39.22% |
| 2010-10-31 | $5.45 Million | +1.00% |
| 2009-10-31 | $5.40 Million | -6.44% |
| 2008-10-31 | $5.77 Million | +749.66% |
| 2007-10-31 | $678.81K | +16.68% |
| 2006-10-31 | $581.79K | +67.07% |
| 2005-10-31 | $348.23K | -21.41% |
| 2004-10-31 | $443.12K | +29.46% |
| 2003-10-31 | $342.29K | -17.33% |
| 2002-10-31 | $414.02K | -82.72% |
| 2001-10-31 | $2.40 Million | +79.21% |
| 2000-10-31 | $1.34 Million | -25.73% |
| 1999-10-31 | $1.80 Million | +28.57% |
| 1998-10-31 | $1.40 Million | +16.67% |
| 1997-10-31 | $1.20 Million | -36.84% |
| 1996-10-31 | $1.90 Million | +533.33% |
| 1995-10-31 | $300.00K | +50.00% |
| 1994-10-31 | $200.00K | -60.00% |
| 1993-10-31 | $500.00K | +66.67% |
| 1992-10-31 | $300.00K | +200.00% |
| 1991-10-31 | $100.00K | 0.00% |
| 1990-10-31 | $100.00K | 0.00% |
| 1989-10-31 | $100.00K | 0.00% |
| 1988-10-31 | $100.00K | 0.00% |
| 1987-10-31 | $100.00K | -50.00% |
| 1986-10-31 | $200.00K | 0.00% |
| 1985-10-31 | $200.00K | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more